Monthly Archives: June 2016

Biosceptre presents at leading Immuno-oncology Investment Conference in Chicago

Biosceptre represented at the 2nd Annual Immuno-Oncology: BD&L and Investment Forum

CHICAGO, USA, June 3, 2016 – Biosceptre, the therapeutic antibody company targeting the nfP2X7 receptor across a broad range of cancers, was in attendance at the leading Immuno-oncology investment forum in Chicago last week in parallel with the ASCO convention.

Biosceptre delivered a 20 minute Investors’¬†Presentation – Biosceptre – Investor Deck Sachs June 2016 – including new preclinical data on the prevalence of the nfP2X7 target and its’ role in cancer, and met with a number of major pharmas and biotech specialists.

As well as making a corporate presentation, Biosceptre also participated in one of the panels at the conference; Dr Shaun McNulty (Biosceptre CSO) represented on the IO Direct Therapeutic Strategies Panel which was co-chaired by James Mulé, Associate Center Director for Translational Research at the H. Lee Moffitt Cancer Center & Research Institute and Paul Rennert, Founder & Principal, SugarCone Biotech LLC, President and CSO, Aleta Biotherapeutics.

Fellow panelists included Francis Kern, Senior Director, External Scientific Affairs, Daiichi Sankyo, Inc., John Haurum, CEO, F-star Biotechnology Ltd., and Juergen Gamer, VP Business Development, APOGENIX AG